Diagnoplex Raises Series A

Diagnoplex, a Swiss developer of molecular cancer diagnostics, has raised CHF 10 million ($8.3m) in Series A funding. Novartis Venture Fund and NeoMed co-led the round, and were joined by Initiative Capital Romandie.

North AmericaUSBriefs